Trial Profile
Study evaluating role of Bortezomib-containing regimens (BCR) for the treatment of newly diagnosed Light-chain Amyloidosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan; Prednisone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology